Sequential Therapy in Renal Cell Carcinoma
Sequential Therapy in Renal Cell Carcinoma
复制标题
DOI：
10.1002/cncr.24241
复制
发表时间：
2009-05-15
期刊：
影响因子：
6.2
通讯作者：
Fizazi, Karim
中科院分区：
文献类型：
--
作者：
Escudier, Bernard;Goupil, Marine Gross;Fizazi, Karim
由于最近批准了几种用于治疗肾细胞癌的药物（包括索拉非尼，舒尼替尼，替西罗莫司，以及在欧洲，贝伐单抗加干扰素），使用序贯治疗已成为常规做法。现在有证据表明，顺序给予这些靶向药物通过在大量患者中诱导肿瘤缩小和延长无进展生存期（PFS）而提供临床益处。然而，关于总生存期（OS）的数据仍悬而未决。通过以适当的顺序添加这些药物，可以预期肾细胞癌患者的总体PFS延长长达27个月，随后OS改善。最近报告称，在一线环境中接受舒尼替尼治疗的患者的OS为26个月。根据目前可用的数据，预期40个月的生存期似乎是可能的，尽管这一假设必须在未来得到证明。Cancer 2009;115（10 suppl）：2321-6. (C)2009年美国癌症协会。
Because of the recent approval of several drugs for the treatment of renal cell carcinoma (including sorafenib, sunitinib, temsirolimus, and, in Europe, bevacizumab plus interferon), the use of sequential therapy has become routine practice. There is now evidence that administering these targeted agents sequentially provides clinical benefit by inducing tumor shrinkage and prolonged progression-free survival (PFS) in a large number of patients. However, data regarding overall survival (OS) are still pending. By adding these drugs in an adequate order, one can expect an increase in overall PFS of up to 27 months and a subsequent improvement in the OS of patients with renal cell carcinoma. It has been recently reported that the OS of patients treated with sunitinib in the first-line setting was 26 months. Expecting a survival of 40 months does appear possible based on currently available data, although this assumption will have to be proven in the future. Cancer 2009;115(10 suppl):2321-6. (C) 2009 American Cancer Society.